2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-181057
    STING-IN-18 98%
    STING-IN-18 is an orally active STING inhibitor. STING-IN-18 exhibits an IC50 of 86 nM against STING in murine RAW-LuciaTM ISG cells. STING-IN-18 inhibits STING activation and blocks downstream signaling pathways. STING-IN-18 suppresses kidney injury and inflammation. STING-IN-18 can be used for the research of autoimmune and inflammatory diseases.
    STING-IN-18
  • HY-181059
    AMPK/mTOR modulator-1 1190602-80-2
    AMPK/mTOR modulator-1, Ginsenoside derivative, is an orally active mTOR inhibitor and AMPK activator. AMPK/mTOR modulator-1 activates AMPK signaling with a Kd of 4.759 μM. AMPK/mTOR modulator-1 promotes M1-like tumor-associated macrophage polarization while suppressing M2-like polarization. AMPK/mTOR modulator-1 can enhance glycolysis. AMPK/mTOR modulator-1 significantly inhibits tumor progression and shows anti-inflammation activity. AMPK/mTOR modulator-1 can be used for the research of colorectal cancer.
    AMPK/mTOR modulator-1
  • HY-181069
    Neuroprotective agent 16 98%
    Neuroprotective agent 16 is a blood-brain barrier-permeable neuroprotective agent. Neuroprotective agent 16 effectively scavenges DPPH and ABTS radicals, with IC50 values of 7.98 μM and 5.50 μM, respectively. Neuroprotective agent 16 exhibits anti-inflammatory, antioxidant, and DNA damage-reducing activities. Neuroprotective agent 16 can be used in research on diseases such as ischemic stroke.
    Neuroprotective agent 16
  • HY-181081
    CHNQD-03005
    CHNQD-03005 is an orally active anti-inflammatory agent. CHNQD-03005 inhibits the expression of iNOS and COX-2, reduces inflammatory signal transduction, suppresses NO production, and downregulates the pro-inflammatory cytokines TNF-α, IL-6 and IL-1β. CHNQD-03005 can be used in the research of inflammatory diseases such as colitis.
    CHNQD-03005
  • HY-181096
    PD-L1-IN-9
    PD-L1-IN-9 is a PD-L1 inhibitor with an IC50 of 110.85 nM. PD-L1-IN-9 has a Kd of 319 nM for human PD-L1 and a Kd of 450 nM for murine PD-L1. PD-L1-IN-9 blocks the PD-1/PD-L1 interaction, restores T cell-mediated anti-tumor immunity, and induces PD-L1 degradation in tumor tissues. PD-L1-IN-9 exhibits anti-tumor activity and can be used in the research of tumors such as melanoma.
    PD-L1-IN-9
  • HY-181110
    MAO-A-IN-4
    MAO-A-IN-4 is a highly selective and reversible inhibitor of monoamine oxidase A (MAO-A), with an IC50 of 0.06 μM against hMAO-A. MAO-A-IN-4 exhibits anti-inflammatory, antioxidant, neuroprotective, and antidepressant activities. MAO-A-IN-4 possesses favorable ADME properties and is suitable for research related to depression.
    MAO-A-IN-4
  • HY-181121
    MK175
    MK175 is an IL-1β inhibitor. MK175 reduces LPS (HY-D1056)-induced IL-1β release in human aortic smooth muscle cells. MK175 is applicable to the research of cardiovascular inflammatory diseases such as atherosclerosis.
    MK175
  • HY-181123
    AS1-6 98%
    AS1-6 is a selective COX-2 inhibitor with an IC50 of 2.7 μM. AS1-6 has an IC50 of 12.6 μM for COX-1. AS1-6 exerts significant anti-inflammatory and analgesic activities. AS1-6 can be used in research on non-steroidal anti-inflammatory agents.
    AS1-6
  • HY-181124
    Idebenone-SS-20 98%
    Idebenone-SS-20 (Idebenone-2S-FrFK-NH2) is a Idebenone (HY-N0303) derivative conjugated to the mitochondria-targeting peptide SS-20. Idebenone-SS-20 shows neuroprotective and anti-inflammatory effects. Idebenone-SS-20 can preserve mitochondrial membrane potential, enhance ATP production, reduce ROS accumulation, maintain mitochondrial morphology and elevate NAD+/NADH ratio. Idebenone-SS-20 confers robust neuroprotection in a murine model of transient middle cerebral artery occlusion. Idebenone-SS-20 can be used for the research of cerebral.
    Idebenone-SS-20
  • HY-181144
    COX-2-IN-65 1408337-43-8
    COX-2-IN-65 is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 10.24 μM. COX-2-IN-65 inhibits Staphylococcus aureus and Escherichia coli growth. COX-2-IN-65 scavenges reactive oxygen species (ROS). COX-2-IN-65 can be used for the researches of bacterial infections and inflammation.
    COX-2-IN-65
  • HY-181155
    Anti-inflammatory agent 111 98%
    Anti-inflammatory agent 111 is a potent anti-inflammatory agent. Anti-inflammatory agent 111 reduces Lipopolysaccharides (LPS) (HY-D1056)-induced i-NOS and COX-2 protein expression, decreases nitric oxide, IL-6, and TNF-α production. Anti-inflammatory agent 111 maintains normal cell viability at bioactive concentrations.Anti-inflammatory agent 111 can be used for the research of inflammation-related disorders.
    Anti-inflammatory agent 111
  • HY-181156
    Anti-inflammatory agent 112 98%
    Anti-inflammatory agent 112 is an inducible nitric oxide synthase (iNOS) inhibitor, a COX-2 inhibitor, and an anti-inflammatory agent. Anti-inflammatory agent 112 suppresses i-NOS and COX-2 protein expression, reduces nitric oxide, IL-6, and TNF-α production, and attenuates lipopolysaccharide (LPS)-induced inflammatory responses. Anti-inflammatory agent 112 can be used for the research of inflammatory disorders.
    Anti-inflammatory agent 112
  • HY-181168
    Lb54 98%
    Lb54 is a caspase-3 and caspase-7 activator with an EC50 of 660.9 nM for human procaspase-3. Lb54 activates caspase-3/7, which cleaves Gasdermin D (GSDMD) at aspartic acid residue 87 to generate a p10 fragment, preventing formation of the pore-forming p30 fragment of GSDMD. Lb54 suppresses GSDMD-mediated pyroptosis through caspase-3/7 activation, thereby attenuating inflammatory responses and conferring protection against sepsis. Lb54 alleviates acute lung injury, and inhibited systemic inflammation by restraining the maturation of monocyte-derived dendritic cells. Lb54 can be used for the research of sepsis.
    Lb54
  • HY-181235
    COX-2/Aromatase-IN-1 98%
    COX-2/Aromatase-IN-1 is a potent dual inhibitor of COX-2 and aromatase. COX-2/Aromatase-IN-1 can simultaneously inhibit COX-2 and aromatase, significantly suppress inflammation and induce proliferation inhibition of breast cancer cells. COX-2/Aromatase-IN-1 exerts anti-breast cancer and anti-inflammatory effects in the MCF-7 breast cancer cell and carrageenan-induced rat paw edema model. COX-2/Aromatase-IN-1 can be used for the study of inflammation and breast cancer.
    COX-2/Aromatase-IN-1
  • HY-181236
    COX-2/Aromatase-IN-2 1622452-45-2 98%
    COX-2/Aromatase-IN-2 is a potent dual inhibitor of COX-2 and aromatase. COX-2/Aromatase-IN-2 can simultaneously inhibit COX-2 and aromatase, suppress inflammation and induce proliferation inhibition of breast cancer cells. COX-2/Aromatase-IN-2 exerts anti-breast cancer and anti-inflammatory effects in the MCF-7 breast cancer cell and carrageenan-induced rat paw edema model. COX-2/Aromatase-IN-2 can be used for the study of inflammation and breast cancer.
    COX-2/Aromatase-IN-2
  • HY-181239
    PTP1B-IN-33 77500-30-2 98%
    PTP1B-IN-33 is a PTP1B inhibitor with a human IC50 of 2.45 μM and over 20-fold selectivity for PTP1B over SHP2. PTP1B-IN-33 enhances π-Alkyl interaction with PTP1B to increase WPD loop closure degree. PTP1B-IN-33 can be used for the research of cancer, diabetes, autoimmune deficiency diseases.
    PTP1B-IN-33
  • HY-181261
    PROTAC CBP/P300 Degrader-2 3102127-45-4 98%
    PROTAC CBP/P300 Degrader-2 (compound 2) is a PROTAC-based CBP/P300 degrader that can be used in the research of cancer, autoimmune, inflammatory, and neurodegenerative diseases.
    PROTAC CBP/P300 Degrader-2
  • HY-181273
    COX-2/5-LOX-IN-7
    COX-2/5-LOX-IN-7 (Hybrids 9) is a COX-2 (IC50 = 3.3 μM)/5-LOX (IC50 = 3.1 μM) inhibitor. COX-2/5-LOX-IN-7 can be used in research on diseases such as inflammation.
    COX-2/5-LOX-IN-7
  • HY-181278
    Deucravacitinib analog 1 1609529-70-5
    Deucravacitinib analog 1 (compound 3), Deucravacitinib (HY-117287) derivative, is a TYK2 allosteric ligand. Deucravacitinib analog 1 binds to the JH2 domain of TYK2. Deucravacitinib analog 1 serves as a starting point for development of TYK2-targeting PROTAC degraders. Deucravacitinib analog 1 can be used for the researches of psoriasis and cancer.
    Deucravacitinib analog 1
  • HY-181279
    PCAF/GCN5 ligand 1 1209224-91-8
    PCAF/GCN5 ligand 1 is a PCAF/GCN5 ligand with high binding affinity. PCAF/GCN5 ligand 1 shows no functional effect on PCAF/GCN5 activity. PCAF/GCN5 ligand 1 undergoes optimization into a potent and selective PCAF/GCN5 ligand GSK4027 (HY-101027).
    PCAF/GCN5 ligand 1
Cat. No. Product Name / Synonyms Application Reactivity